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Abstract
Context: Older adults are underrepresented in clinical research. To assess therapeutic efficacy in older patients, some
randomized controlled trials (RCTs) include older adults only.
Objective: To compare treatment effects between RCTs including older adults only (elderly RCTs) and RCTs including all
adults (adult RCTs) by a meta-epidemiological approach.
Methods: All systematic reviews published in the Cochrane Library (Issue 4, 2011) were screened. Eligible studies were
meta-analyses of binary outcomes of pharmacologic treatment including at least one elderly RCT and at least one adult RCT.
For each meta-analysis, we compared summary odds ratios for elderly RCTs and adult RCTs by calculating a ratio of odds
ratios (ROR). A summary ROR was estimated across all meta-analyses.
Results: We selected 55 meta-analyses including 524 RCTs (17% elderly RCTs). The treatment effects differed beyond that
expected by chance for 7 (13%) meta-analyses, showing more favourable treatment effects in elderly RCTs in 5 cases and in
adult RCTs in 2 cases. The summary ROR was 0.91 (95% CI, 0.77–1.08, p = 0.28), with substantial heterogeneity (I2 = 51% and
t2 = 0.14). Sensitivity and subgroup analyses by type-of-age RCT (elderly RCTs vs RCTs excluding older adults and vs RCTs of
mixed-age adults), type of outcome (mortality or other) and type of comparator (placebo or active drug) yielded similar
results.
Conclusions: The efficacy of pharmacologic treatments did not significantly differ, on average, between RCTs including
older adults only and RCTs of all adults. However, clinically important discrepancies may occur and should be considered
when generalizing evidence from all adults to older adults.
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Introduction
The number of people aged 60 years and older now is twice the
number in 1980. By 2050, the number of people 80 years and
older will be four-fold the current number [1]. The life expectancy
has increased during the last decades and thus, more older people
may need medical interventions.
The care of older patients presents a challenge for evidence-
based medicine [2]: the body of evidence concerning the efficacy
of therapeutic interventions in older adults is usually small because
these patients are largely underrepresented in clinical trials
[3,4,5,6,7,8,9]. Nearly three-quarters of trials reported in major
journals excluded older patients [10]. This exclusion is often
poorly justified despite the availability of methods for enhancing
their recruitment [11,12,13,14] and several authorities highlight-
ing the need for representative samples of older adults in
randomized controlled trials (RCTs) [2,15,16,17] and even the
need for randomized trials including older adults only [18,19].
In the absence of evidence for older adults, pharmacologic
results for younger adults are commonly extrapolated to older
patients assuming that the efficacy is the same. However, this
practice may not be valid because of physiological changes
associated with aging that affect the pharmacokinetics of drugs,
including multiple co-morbidities in older people and unpredict-
able treatment responses [20,21]. Indeed, the Randomized
Aldactone Evaluation Study [22] demonstrated reduced mortality
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with spironolactone administration in patients with congestive
heart failure, with average age 60 years. In contrast, data from
several observational cohorts of patients with congestive heart
failure who were 13 years older revealed that spironolactone was
associated with an almost four-fold increase in number of deaths
due to hyperkaliemia [23]. We need to be able to draw on the
results of good-quality research to inform best practice in the
management of older adults.
In this study, we assessed empirically whether treatment effects
differed between RCTs including older adults only (elderly RCTs)
andRCTs including all adults (adult RCTs) that were performed for
the same medical problem and with the same pharmacological
therapeutic interventions, using a meta-epidemiological approach
[24].
Materials and Methods
We performed a meta-epidemiological study to compare
treatment effect estimates between elderly RCTs and adult RCTs
[25].We identified a large number of meta-analyses that included at
least one elderly RCT and at least one adult RCT and concerned a
variety of conditions and therapeutic interventions. We recorded
whether individual RCTs included older adults only or not. For each
meta-analysis, we compared summary odds ratios (ORs) for elderly
RCTs and adult RCTs by calculating a ratio of ORs (ROR). A
summary ROR was estimated across all meta-analyses.
This methodology has been used previously to establish
empirical evidence of bias in estimating treatment effects (e.g.,
double blinding, intent-to-treat analyses and allocation conceal-
ment [26,27,28,29], single vs multi-center [30,31], randomized vs
non-randomized trials [32]) and recently to compare efficacy in
trials of children and adults [33].
Selection of meta-analyses
One reviewer screened all systematic reviews published in the
Cochrane Library in the Cochrane Database of Systematic
Reviews (Issue 4, 2011) concerning all medical domains assessing
pharmacological therapeutic interventions. Reviews for Cochrane
Groups working on pregnancy, neonatality, fertility, cancer
childhood, organization care and public health were excluded.
Eligible reviews reported at least one meta-analysis of a binary
outcome for at least 3 RCTs, of which 1 was specific to older
adults (elderly RCT) and 1 not specific to older adults (adult RCT).
We focused on Cochrane reviews because some studies have
shown that these have high methodological quality and are well
reported [34].
One reviewer selected reviews in 3 steps: examining the title,
abstract and full-text for potentially relevant reviews. For each
eligible systematic review, we systematically screened the ‘‘Char-
acteristics of included studies’’ table to identify elderly RCTs as
follows: the authors clearly reported the population as ‘‘older’’,
‘‘geriatric’’ or ‘‘elderly’’ or they defined the lower age limit as
selection criteria or the minimum age of included patients as
$60 years. If the previous information was not available, we also
considered trials with mean patient age $75 years as elderly
RCTs. For adult RCTs, we distinguished 4 categories: trials
excluding older adults (defined as RCTs excluding older adults),
trials including both older adults and non-older adults (RCTs of
mixed-age adults), unclear or unspecified age recruitment and
children-specific trials.
Data extraction
For each eligible meta-analysis, we extracted the following
information from each Cochrane review: clinical domain,
experimental and control interventions (placebo, no treatment,
active drug), primary binary efficacy outcome, and number of
included RCTs.
For each RCT, we extracted the age category reported in Table
1 of the Cochrane review, as described: elderly RCT or adult
RCT (including RCTs excluding older adults, RCTs of mixed-age
adults, unclear RCTs and children-specific RCTs). We also
extracted the sample size and the number of patients and events
per each study arm from the forest plot of the meta-analysis.
If more than 1 primary outcome was reported or if the primary
outcome was not specified among several binary outcomes, we
selected the first outcome presented in the Results section. When 2
active interventions were compared, identification of the experi-
mental and control interventions was based on interpretation by
the authors of the Cochrane review. If this identification was not
clear, we identified which intervention was first discovered
according to PubMed first indexing, and this was considered the
control intervention. One of the authors extracted the data.
Data synthesis and analysis
We used a two-stage model to compare treatment effect
estimates for elderly RCTs and adult RCTs.
Treatment effect estimates for elderly RCTs and adult
RCTs
For each included meta-analysis, we estimated the 2 summary
odds ratios (ORs) comparing the experimental and the control
interventions for elderly RCTs and adult RCTs separately. In
cases of many trials for an age group, we combined the trials by
random-effects models [35]. Heterogeneity across RCTs was
assessed by means of the I2 statistic and the between-RCT
variance t2. Outcome events were re-coded so that an OR ,1
indicated a beneficial effect of the experimental intervention.
When appropriate, we used a continuity correction [36].
For each meta-analysis, we evaluated whether the difference in
ORs between elderly RCTs and adult RCTs was larger than
would be expected by chance alone using z scores. We also
assessed in how many cases the summary OR for elderly RCTs
was less than half the summary OR for adult RCTs and in how
many cases the summary OR for elderly RCTs was twice the
summary OR for adult RCTs.
Meta-analysis of ratios of odds ratios between elderly
RCTs and adult RCTs
For each meta-analysis, we estimated an ROR and associated
standard error [37] from the summary ORs estimated for elderly
RCTs and adult RCTs. A ROR,1 indicated that elderly RCTs
yielded larger estimates of the intervention effect than did adult
RCTs. Then we combined all RORs across meta-analyses by
using a random-effects meta-analysis model [38]. Heterogeneity
across meta-analyses was assessed by means of the I2 statistic and
the between–meta-analyses variance t2. We also computed a
prediction interval for the summary ROR [39].
Age-group RCT analyses
In our main analysis, we compared elderly RCTs and adult
RCTs. In a complementary analysis, we compared elderly RCTs
to RCTs excluding older adults and to RCTs of mixed-age adults.
Unclear RCTs were alternatively considered as RCTs excluding
older adults or as RCTs of mixed-age adults.
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Exploration of heterogeneity
We used a graphical method to identify meta-analyses that
contributed considerably to the overall heterogeneity across RORs
and that could strongly influence the overall summary ROR [40].
In a sensitivity analysis, we excluded the most heterogeneous and
influential meta-analyses and re-estimated the summary ROR and
the heterogeneity statistics across meta-analyses. To further
explore heterogeneity, we performed 2 pre-specified subgroup
analyses by type of comparator treatment (active drug vs placebo
and/or usual care or no treatment) and type of outcome (mortality
vs other outcomes).
Statistical analysis
There is no validated method of power calculation for meta-
epidemiological analyses. Statistical power of a meta-epidemio-
logical analysis would depend on the true ROR, the number of
meta-analyses and trials, the distribution in each meta-analysis of
trials with and without the characteristic of interest, and the
heterogeneity between and within studies. We arbitrarily prespec-
ified a sample size of 50 meta-analyses.
The analyses involved the two-stage comparison described
above and were consolidated with a one-stage multilevel model (ie,
a hierarchical logistic regression model with mixed effects) [41].
We used R v2.15.1 [42] for all analyses and the packages meta
[43], metafor [44] and lme4 [45].
Results
Of the 3, 403 systematic reviews identified from the Cochrane
Library, 55 were included (Figure S1). Their characteristics are
in Table S1. Fifteen (27%) concerned psychiatry, 14 (25%)
cardiovascular diseases and 9 (16%) neurology. In total, 35 (64%)
meta-analyses compared pharmacologic treatment with placebo or
no treatment. The 55 meta-analyses involved 524 RCTs overall
(Figure S1): 90 (17%) were elderly RCTs, and 434 were adult
RCTs, including 73 RCTs excluding older adults, 224 RCTs of
mixed-age adults, 133 unclear RCTs and 4 children-only RCTs.
The median sample size was 91 patients (min-max 18–6,706) for
elderly RCTs and 82 (10–23,323) for adult RCTs. The total
number of included patients was 199,760, with 21% for elderly
RCTs and 79% for adult RCTs.
Treatment effect estimates for elderly RCTs and adult
RCTs
Among the 55 meta-analyses, for 48, the summary ORs did not
differ between elderly RCTs and adult RCTs. However, the
summary ORs differed beyond chance for 7 (13%) meta-analyses
(Figure S2), showing more favourable treatment effects in elderly
RCTs for 5 meta-analyses (CD000096, CD00424, CD001886,
CD003781, CD008120) and in adult RCTs for 2 meta-analyses
(CD002747, CD007503). The characteristics of the 7 correspond-
ing reviews are in Table S2.
When we considered the magnitude of treatment effect
estimates, the summary OR for elderly RCTs was less than half
the summary OR for adult RCTs for 9 (16%) meta-analyses. In
contrast, the summary OR for elderly RCTs was at least twice the
summary OR for adult RCTs for 8 (15%) meta-analyses.
Meta-analysis of RORs between elderly RCTs and adult
RCTs
The results of the meta-analysis of RORs are in Figure S3.
The summary ROR across all 55 included meta-analyses was 0.91
(95% CI, 0.77–1.08, p= 0.278), with substantial heterogeneity
(I2 = 51.1% and t2 = 0.137). The 95% prediction interval, which
provides a predicted range for the true ROR in an individual
meta-analysis, was 0.43 to 1.92.
Age-group RCT analyses
In comparing elderly RCTs with RCTs excluding older adults
and RCTs of mixed-age adults, the summary ROR was 0.88 (95%
CI 0.63–1.17, n = 29 reviews) and 0.93 (0.76–1.15, n= 38 reviews),
respectively. The hierarchical multilevel modeling approach
yielded similar summary RORs (elderly RCTs vs RCTs excluding
older adults, 0.88, 0.70–1.09; elderly RCTs vs RCTs of mixed-age
adults, 0.95, 0.83–1.09). Alternatively, when we considered trials
for which the age category was unclear as RCTs excluding older
adults or RCTs of mixed-age adults, we did not find any difference
(Appendix S1).
Exploration of heterogeneity
Three meta-analyses (CD008120, CD003781, and CD002747)
accounted for most of the heterogeneity (50.0%) and had a strong
influence on the sROR (65% of the sum of the influences; Figure
in Appendix S1). In a sensitivity analysis, the exclusion of these 3
meta-analyses strongly reduced the heterogeneity across RORs
(I2 = 2%; t2 = 0.0035), but the summary ROR was only slightly
modified (0.99, 95% CI 0.90–1.10). The characteristics of these
reviews are in Table S2.
Subgroup analysis by type of control group revealed no
statistically significant difference, on average, in treatment effects
estimates between elderly RCTs and adult RCTs with control
groups of placebo, no treatment or usual care (summary ROR
0.87; 95% CI 0.68–1.11) or an active drug (0.95; 0.82–1.10).
Subgroup analysis by type of outcome yielded similar results when
assessing mortality (1.11; 0.90–1.36) and other outcomes (0.95;
0.82–1.10).
Discussion
For a sample of 55 Cochrane systematic reviews, we performed
an empirical evaluation of the relative treatment effect estimates of
pharmacological therapeutic interventions between RCTs that
included older adults only and RCTs of the general adult
population. In 7 cases, treatment effect estimates differed
significantly between elderly RCTs and adult RCTs, showing
more favourable treatment effects in elderly RCTs for 5 meta-
analyses and in adult RCTs for 2 meta-analyses. Treatment effects
estimates did not differ significantly, on average, between elderly
RCTs and adult RCTs.
For some elderly RCTs, the intervention efficacy would have
been overestimated if based on adult RCTs (meta-analyses
CD002747, CD007503). In these 2 meta-analyses, the experi-
mental treatment may have suggested benefit in the global
population, but for RCTs specific to older adults, the control
treatment may have been more beneficial than the experimental
treatment. The first identified situation concerned women with
metastatic breast cancer. For adult RCTs, the results of the meta-
analysis would have leaned toward chemotherapy alone, whereas
for older women, the results would have favored endocrine
therapy alone. This situation is unique in terms of menopausal
status, which depends on the age of women. The second situation
involved psychiatry (antidepressants for depression in physically ill
people). However, in this meta-analysis, one elderly RCT involved
patients in a general medical ward for older adults, whereas
another included RCTs of mostly outpatients with chronic diseases
(chronic prostatitis, Parkinson disease, multiple sclerosis and
Randomized Trials Enrolling Older Adults Only
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cancer). The type of depression could differ among these types of
illnesses.
The lack of evidence from elderly RCTs may have 2
consequences: the use of medications with risks that are likely to
out-weight benefits and undertreatment of older patients, which
may result in a lack of improvement [46,47,48,49]. In practice, the
allocation of a pharmacological treatment for an older patient is
guided by determination of the absolute benefits and harm in
individual patients. Unfortunately, many reports of RCTs fail to
provide detailed adverse effects data, and the quality of those that
do is poor [50,51,52,53].
The definition of older patients is controversial. For example,
the European Medicines Agency arbitrarily defines its scope as
patients 65 years of age (standard retirement age) or older [16],
the World Health Organization proposed a cut-off of 60 years or
older [1], and several medical domains have a cut-off of 80 years
and older [54]. At the present and hopefully in the next decades,
people in their 60 s or even 70 s will become healthier.
Nevertheless, because of the physiological changes of aging (eg,
weight, body composition, decreased glomerular filtration rate)
and the increased risk of neurodegenerative diseases, diabetes, and
cardiovascular events, for example, this age group differs from
younger adults. Although aging is a progressive process, the
definition of older adults in RCTs should be based on available
and relevant indicators.
Our study contains some limitations. First, for consistency, we
considered only reviews with binary efficacy outcomes only;
however, this involves a large portion of clinically useful outcomes
in clinical trials. Second, some Cochrane reviews did not provide
information on the age of trial populations and, in theory, some of
these meta-analyses might have been eligible if they included both
elderly RCTs and adult RCTs. However, screening thousands of
trials with unspecified age distribution would have been difficult,
with uncertain yield; therefore, we depended on the information
collected and recorded by the Cochrane authors of reviews to
decide whether to include the review. The quality of Cochrane
reviews is generally considered very good [55]. Third, in our main
analyses, we included RCTs with ‘‘unspecified/unclear’’ age
group from each eligible meta-analysis, which accounted for 25%
of the trials, but excluding or reclassifying them in sensitivity
analyses with adult RCTs yielded similar results. Fourth, the lack
of data did not allow for performing formal comparisons of
different older age groups (eg, older vs very older). Fifth, the results
of both elderly RCTs and adult RCTs may be biased for diverse
reasons, and the meta-analysis results may also be affected. Some
reviews perform quality and bias assessments, but these assess-
ments can differ across reviews, [56] and associations of reported
quality with treatment effects may be tenuous [57]. However,
biases are unlikely to differ in elderly RCTs and adult RCTs.
Our findings reflect only efficacy of treatment as measured in
randomized trials. This efficacy may differ from effectiveness in
clinical practice because patients included in trials may differ from
patients in clinical practice. Some meta-confounding factors could
bias our findings. These factors may be related to differences
between included trials (concerning patient inclusion critera, the
risk of bias of trials). Elderly patients included in elderly RCTs may
be over-selected as compared with other adults included in
general-age adult trials because of inclusion criteria in RCTs (eg,
comorbities, illness severity, physiological functions, in- and
outpatients). Taking such biases into account in the analyses
may be difficult, but identifying such confounders may be useful.
Therefore, we checked the co-morbidities used as selection criteria
of trials included in meta-analyses. No trial had been excluded
because of co-morbidities or physical or biological age-related
dysfunctions. Nevertheless, we did not check patient exclusion
criteria for individual elderly RCTs. Our exploratory framework
does not allow for concluding that pharmacological treatment
effects in elderly patients are similar to those in non-elderly
patients because we explored trials that included only elderly
patients as compared with trials that included adults without
lower-age–inclusion criteria. Similar results of treatment effect
estimates for pharmacologic RCTs including elderly patients only
and adult RCTs were average estimates, but discrepancies in
treatment effects can occur. The extent and direction of the
difference were unpredictable, and extrapolation of evidence from
adult RCTs to elderly RCTs can sometimes be tenuous.
As Scott and Guyatt state, [2] ‘‘It is wisest to assume similar relative
treatment effects in older and younger patients unless there is compelling evidence
of age-related differences.’’ Identification of interventions that do not
provide any clinical benefit in older versus younger adults or are
potentially harmful in older adults is important. Similarly, current
European regulations require mandatory studies of older adults for
all drugs,15 and the European Medicines Agency plans to make
publicly available all results of clinical trials of older adults, but this
move does not guarantee that sufficiently large trials will be
conducted. Generation of large-scale evidence for geriatric
indications is warranted.
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Figure S1 Flow-chart of included reviews.
(EPS)
Figure S2 Comparison of the summary odds ratios
(ORs; and 95% confidence intervals [95% CIs]) for
RCTs specifically including and not including older
adults (elderly RCTs and adult RCTs). Summary ORs were
estimated with random-effects meta-analysis. Data in blue indicate
meta-analyses for which the difference between summary ORs in
elderly RCTs and in adult RCTs was beyond what would be
expected by chance alone. Labels in bold indicate meta-analyses
for which the magnitude of the treatment effect estimates was $2
or #50%. OR,1 favors experimental treatment and OR
.1 favors the control treatment. *One meta-analysis showed
the experimental intervention to be significantly worse than the
control (CD003348 ‘‘Patient controlled opioid analgesia versus
conventional opioid analgesia for postoperative pain’’).
(TIFF)
Figure S3 Meta-analysis of ratios of ORs for elderly
RCTs and adult RCTs. The width of the diamond is the 95%
confidence interval for the true summary ROR and the dotted line
is the prediction interval which indicates the possible ROR in an
individual meta-analysis.
(TIFF)
Table S1 Description of meta-analyses including at
least 1 elderly randomized controlled trial (RCT specific
to older adults) and including at least 1 adult RCT (not
specific to older adults).
(DOC)
Table S2 Characteristics of meta-analyses with signif-
icantly different treatment effect estimates between
elderly RCTs and adult RCTs. OR: odds ratio; 95% CI:
95% confidence interval, * the 3 reviews that accounted for most
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